U.S. Merck Looks For Developing Country Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's second-quarter results demonstrate the risks and rewards of becoming less U.S.-centric. Emerging markets expansion and new product launches outside of the U.S. drove growth, but EU price cuts dampened revenues and profits.
You may also be interested in...
Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)
Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data
Western Companies' Perspectives On Emerging Markets: Execution Trumps Strategy - PharmAsia Summit
SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco
Strong Diabetes Franchise Growth Highlights Solid Third Quarter For Merck
Three new product launches also were among the bright spots in a quarter in which the pharma posted net income of $342 million.